interferon alfa-2b
interferon alfa-2b: 5 clinical trials tracked.
interferon alfa-2b evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about interferon alfa-2b, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 3 study sponsors
Related indications
No linked indication is available.
Clinical Trials (5)
A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance
Primary endpoint: Objective Response Rate (ORR)
Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19
Primary endpoint: Number of Participants With Adverse Events (AEs)
Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen
Primary endpoint: Count of tumor infiltrating CD8+ lymphocytes
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
Primary endpoint: Recurrence-free Survival (RFS; Arm B [HDI] vs. Arm C [LIP])
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Primary endpoint: 5-year Relapse-free Survival Rate